BARCELONA, Spain--(BUSINESS WIRE)--Corindus, developer and marketer of proprietary remote control catheterization systems, announced today the appointment of Frank Martin as the new CEO and the enrollment of an additional 11 patients to its clinical trials.
The company completed clinical trials last week with its CorPath(TM) system in Mumbai, India. Dr. Kumar who led the clinical trial at Dr LH Hirnandani Hospital commenting on these 11 cases: “The CorPath(TM) system allowed me to operate remotely from the control room while not being exposed to radiation. I precisely navigated the guidewires and positioned the stents. I am excited to be a part of this trial and look forward to more physicians using CorPath(TM) in their PCI procedures.”
Mr. Martin, who has also served as a Director in Corindus, brings to the company over 30 years of business leadership with both public and private companies. Over the span of his career Mr. Martin has founded and managed startup companies CorMedica, manufacturer of catheter based navigation systems, Advanced Biomedical Instruments and PLC Systems and most recently served as Executive Chairman of Cappella.
Commenting on his appointment to Corindus CEO Mr. Martin said, “Corindus’s CorPath(TM) is the third generation of medical robotics. I am honored to lead Corindus to its next phase as the first provider of open platform, remote controlled manipulating systems for use in the cath lab.”
Mr. Tal Wenderow co-founder who served as the CEO will continue as the COO and VP of Business Development of the company.
Corindus will present its CorPath(TM) system together with Simbionix simulator during the annual PCR conference May 22-25, 2007 in Barcelona, Spain. Corindus invites participants to visit booth G23 at the exhibit hall to gain experience in using the system with the simulator.
About Corindus
Corindus designs, manufactures and commercializes patented remote control systems for percutaneous applications. Its CorPath(TM) system enables the physician to perform catheterization procedures from a remote location beyond the radiation zone. Compatible with state-of-the-art cardiology products and cath lab imaging technologies, CorPath(TM) mechanically maneuvers devices through patients’ arteries as specified by the physician at a remote workstation. The proprietary technology utilizes physician fluoroscopic control similar to routine practice to allow maneuvering and torquing of cath lab devices. Initial clinical trials have demonstrated CorPath’s safety and efficacy. Unique to CorPath(TM) is the simplicity of integration into existing cath lab systems without installation costs or downtime.
The CorPath(TM) system requires regulatory clearance and currently is used for investigational purposes only.
Contact: Corindus, Inc. Tal Wenderow, 617-581-6210 COO, VP Business Development talw@corindus.com www.corindus.com
Source: Corindus
